Table 3.

Univariate and multivariate analyses of progression-free survival and cancer-specific survival in patients with upper tract urothelial carcinoma.

	Progression-Free Survival						Cancer-Specific Survival
Variable	Univariate			Multivariate			Univariate			Multivariate
	HR	95 %CI	p	HR	95 %CI	p	HR	95 %CI	p	HR	95 %CI	p
All cases (n = 99)
Sex (male/female)	1.33	0.68–2.61	0.40				1.33	0.62–2.85	0.46
Age (70</≤70)	1.38	0.72–2.64	0.33				1.65	0.78–3.48	0.19
Tumor site (pelvis/ureter)	0.80	0.41–1.55	0.50				0.83	0.40–1.72	0.61
Tumor grade (high/low)	4.44	1.07–18.51	0.041 **	5.52	1.29–23.72	0.022 **	7.77	1.06–57.18	0.044 **	6.95	0.94–51.23	0.057 *
pT stage (MI/NMI)	17.30	4.15–72.14	<0.001 **	8.5	1.94–37.31	0.0046 **	1.09 × 109	13.52–Inf	<0.001 **	5.76 × 109	(6.39–7.60) × 1038	<0.001 **
Lymphovascular invasion (Yes/No)	5.84	2.88–11.83	<0.001 **	2.54	1.10–5.84	0.028 **	5.62	2.50–12.66	<0.001 **	1.86	0.77–4.48	0.16
Lymph node metastasis (Yes/No)	4.40	2.07–9.36	<0.001 **	2.06	0.95–4.47	0.068 *	2.74	1.17–6.40	0.020 **	1.07	0.43–2.63	0.89
Adjuvant chemotherapy (Yes/No)	1.13	0.56–2.28	0.73				1.08	0.49–2.37	0.85
Trop-2 strong expression	0.18	0.055–0.58	0.0043 **	0.29	0.087–0.97	0.045 **	0.16	0.039–0.69	0.014 **	0.31	0.072–1.36	0.12

Abbreviations: CI, confidence interval; HR, hazard ratio; Inf, Infinity; MI, muscle invasive; NMI, non–muscle invasive; ** p < 0.05 and * p < 0.1.